Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

1. Sweeney, C.
2. Bracarda, S.
3. Sternberg, C.N.
4. Chi, K.N.
5. Olmos, D.
6. Sandhu, S.
7. Massard, C.
8. Matsubara, N.
9. Alekseev, B.
10. Parnis, F.
11. Atduev, V.
12. Buchschacher, G.L.
13. Gafanov, R.
14. Corrales, L.
15. Borre, M.
16. Stroyakovskiy, D.
17. Alves, G.V.
18. Bournakis, E.
19. Puente, J.
20. Harle-Yge, M.-L.
21. Gallo, J.
22. Chen, G.
23. Hanover, J.
24. Wongchenko, M.J.
25. Garcia, J.
26. de Bono, J.S.
27. Show all authors +